The amount of cash generated by global public and private biopharmaceutical companies was up significantly in the third quarter compared to the second quarter. Read More
The EMA and the European Commission (EC) updated the annex to the EC guideline on labeling excipients used in human drugs, adding five new excipients that must be declared in the labeling and new safety warnings for 10 excipients already included in the annex. Read More
Evolus Inc., of Santa Barbara, Calif., presented data at the American Society of Plastic Surgeons meeting in Orlando, Fla., and the American Society for Dermatologic Surgery meeting in Chicago, from phase II and phase III studies of its botulinum toxin candidate, prabotulinumtoxinA 900 kilodalton neuromodulator, in glabellar lines. Read More
Framing it as a victory of the weak over the powerful and the poor over the rich, California Gov. Jerry Brown Monday signed into law a bill that will require transparency – from biopharma companies, that is – about price increases for prescription drugs. Read More
Approval by the FDA of Flexion Therapeutics Inc.'s Zilretta whetted the appetite for more non-opioid drugs, the lack of which has left officials at pain-focused Centrexion Therapeutics Inc. "awestruck," Chief Medical Officer Randall Stevens told BioWorld. Read More
The platforms are distinct but the end game is identical. Rare disease company Allena Pharmaceuticals Inc., anti-infectives developer Spero Therapeutics LLC and cancer therapy hopeful Erytech Pharma SA filed for U.S. IPOs, joining Ablynx NV, which filed days earlier, to extend the biopharma trek to the public markets into the fourth quarter. Read More
HONG KONG – China's State Council released a set of guidelines for innovation in new drug and medical device development. The new regulations round up some recent regulatory updates, providing substantial and practical guidance to further push the innovation in China's health care industry. Read More
PERTH, Australia – Australian biotech Propanc Biopharma Inc. is advancing its lead product, PRP, toward the clinic in ovarian and pancreatic cancers. The Melbourne-based company reported that recent studies show that the once-daily intravenous combo of pancreatic proenzymes trypsinogen and chymotrypsinogen reduced epithelial to mesenchymal transition (EMT) markers, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of cancer stem cells. Read More
Strongbridge Biopharma plc, of Trevose, Pa., said it closed its underwritten public offering of 4 million ordinary shares for total net proceeds of approximately $23.4 million. Read More
Thrombogenics NV, of Leuven, Belgium, said preclinical data published in Experimental Eye Research testing the murine form of THR-317 in various animal models of diabetic retinopathy (DR) showed that the anti-PlGF antibody shared a common pharmacology toward vascular leakage in comparison to VEGF inhibitors, which are currently the standard of care for DR. Read More
Provention Bio Inc., of Lebanon, N.J., appointed Andrew Drechsler chief financial officer; Francisco Leon chief scientific officer; and Eleanor "Leni" Ramos chief medical officer and chief operating officer. Read More
